Search

Your search keyword '"Salandini, M"' showing total 8 results
Start Over Author "Salandini, M"
8 results on '"Salandini, M"'

1. L‐DOPA‐induced dyskinesias, motor fluctuations and health‐related quality of life: the COPARK survey

Author

Perez‐Lloret, S., Negre‐Pages, L., Damier, P., Delval, A., Derkinderen, P., Destée, A., Meissner, W. G., Tison, F., Rascol, O., Spampinato, U, Damier, P, Derkinderen, P, Rascol, O, Rey‐Zermati, V, Soulages, X, Azais‐Vuillemin, C, Stambouli, N, Rouane, R, Salandini, M, Boulesteix, M, Barreda, M, Castan, D, Ojero‐Senard, A, Angibaud, G, Balague, P, Danielli, A, Attane, N, Faucheux, M, Henry, P, Rougie, H, Jardillier, B, Azais, F, Damase, L, Destee, A, Lejeune, P, Delabrousse‐Mayoux, M, Bonenfant, S, Darmanaden, R, Robinson, A, Gaujard, E, Puymirat, E, Goumard, E, Godin, H, Latxague, C, Deligny, C, Lebouvier, T, Lanctin‐Garcia, C, Roy, M, Verbist‐Talmant, V, and Bertout, P

Published
2017
Full Text
View/download PDF

2. Changes in body composition during neoadjuvant therapy can affect prognosis in rectal cancer patients: An exploratory study

Author

De Nardi, P, Salandini, M, Chiari, D, Pecorelli, N, Cristel, G, Damascelli, A, Ronzoni, M, Massimino, L, De Cobelli, F, Braga, M, De Nardi P., Salandini M., Chiari D., Pecorelli N., Cristel G., Damascelli A., Ronzoni M., Massimino L., De Cobelli F., Braga M., De Nardi, P, Salandini, M, Chiari, D, Pecorelli, N, Cristel, G, Damascelli, A, Ronzoni, M, Massimino, L, De Cobelli, F, Braga, M, De Nardi P., Salandini M., Chiari D., Pecorelli N., Cristel G., Damascelli A., Ronzoni M., Massimino L., De Cobelli F., and Braga M.

Abstract

Aim: To establish the correlation between changes in body composition after neoadjuvant chemoradiotherapy (nCRT) and postoperative outcomes, in patients with advanced low rectal cancer. Methods: Patients with clinical stage T≥3 or N+ rectal cancer who underwent nCRT and surgical resection were studied. Skeletal muscle, visceral, and subcutaneous fat cross-sectional area were measured by computed tomography before and after nCRT. Postoperative morbidity, pathologic response to nCRT, overall and disease-free survival was assessed. Results: Fifty-two patients, median age 62 (range 32-79) were studied. A skeletal muscle loss >2% significantly correlated with a shorter disease-free survival both in the overall population (P = 0.048) and in the subgroup of N0 patients (P = 0.048). A subcutaneous fat loss >5% was also associated with a shorter disease-free survival (P = 0.012) in the whole population. Conclusions: Skeletal muscle loss, after neoadjuvant chemoradiotherapy, negatively impacts on disease-free survival in surgically treated rectal cancer patients.

Published
2020

3. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer

Author

Sandini, M, Patino, M, Ferrone, C, Alvarez-Perez, C, Honselmann, K, Paiella, S, Catania, M, Riva, L, Tedesco, G, Casolino, R, Auriemma, A, Salandini, M, Carrara, G, Cristel, G, Damascelli, A, Ippolito, D, D'Onofrio, M, Lillemoe, K, Bassi, C, Braga, M, Gianotti, L, Sahani, D, Fernandez-Del Castillo, C, Sandini M., Patino M., Ferrone C. R., Alvarez-Perez C. A., Honselmann K. C., Paiella S., Catania M., Riva L., Tedesco G., Casolino R., Auriemma A., Salandini M. C., Carrara G., Cristel G., Damascelli A., Ippolito D., D'Onofrio M., Lillemoe K. D., Bassi C., Braga M., Gianotti L., Sahani D., Fernandez-Del Castillo C., Sandini, M, Patino, M, Ferrone, C, Alvarez-Perez, C, Honselmann, K, Paiella, S, Catania, M, Riva, L, Tedesco, G, Casolino, R, Auriemma, A, Salandini, M, Carrara, G, Cristel, G, Damascelli, A, Ippolito, D, D'Onofrio, M, Lillemoe, K, Bassi, C, Braga, M, Gianotti, L, Sahani, D, Fernandez-Del Castillo, C, Sandini M., Patino M., Ferrone C. R., Alvarez-Perez C. A., Honselmann K. C., Paiella S., Catania M., Riva L., Tedesco G., Casolino R., Auriemma A., Salandini M. C., Carrara G., Cristel G., Damascelli A., Ippolito D., D'Onofrio M., Lillemoe K. D., Bassi C., Braga M., Gianotti L., Sahani D., and Fernandez-Del Castillo C.

Abstract

IMPORTANCE Sarcopenia and sarcopenic obesity have been associated with poor outcomes in unresectable pancreatic cancer (PC). Neoadjuvant treatment (NT) is used increasingly to improve resectability; however, its effects on fat and muscle body composition have not been characterized. OBJECTIVES To evaluate whether NT affects muscle mass and adipose tissue in patients with borderline resectable PC (BRPC) and locally advanced PC (LAPC) and determine whether there were potential differences between patients who ultimately underwent resection and those who did not. DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort study conducted at 4 academic medical centers, 193 patients with BRPC and LAPC undergoing surgical exploration after NT who had available computed tomographic scans (both at diagnosis and preoperatively) and confirmed pancreatic ductal adenocarcinoma were evaluated. The study was conducted from January 2013 to December 2015. Data analysis was performed from September 2016 to May 2017. Measurement of body compartments was evaluated with volume assessment software before and after NT. A radiologist blinded to the patient outcome assessed the areas of skeletal muscle, total adipose tissue, and visceral adipose tissue through a standardized protocol. EXPOSURES Receipt of NT. MAIN OUTCOMES AND MEASURES Achievement of pancreatic resection at surgical exploration after the receipt of NT. RESULTS Of the 193 patients with complete radiologic imaging available after NT, 96 (49.7%) were women; mean (SD) age at diagnosis was 64 (11) years. Most patients received combined therapy with fluorouracil, irinotecan, oxaliplatin, leucovorin, and folic acid (124 [64.2%]) and 86 (44.6%) received chemoradiotherapy as well. The median interval between pre-NT and post-NT imaging was 6 months (interquartile range [IQR], 4-7 months). All body compartments significantly changed. The adipose compound decreased (median total adipose tissue area from 284.0 cm2; IQR, 171.0-414.0

Published
2018

6. Changes in body composition during neoadjuvant therapy can affect prognosis in rectal cancer patients: An exploratory study

Author

Damiano Chiari, Paola De Nardi, Mariachiara Salandini, Francesco De Cobelli, Luca Massimino, Giulia Cristel, Anna Damascelli, Nicolò Pecorelli, Marco Braga, Monica Ronzoni, De Nardi, P, Salandini, M, Chiari, D, Pecorelli, N, Cristel, G, Damascelli, A, Ronzoni, M, Massimino, L, De Cobelli, F, Braga, M, De Nardi, P., Salandini, M., Chiari, D., Pecorelli, N., Cristel, G., Damascelli, A., Ronzoni, M., Massimino, L., De Cobelli, F., and Braga, M.

Subjects
Adult, Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Population, Body composition change, Subcutaneous fat, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, In patient, Rectal cancer, Stage (cooking), education, Neoadjuvant therapy, Aged, Retrospective Studies, education.field_of_study, Rectal Neoplasms, business.industry, Skeletal muscle loss, Skeletal muscle, Chemoradiotherapy, Adjuvant, Middle Aged, Prognosis, medicine.disease, Neoadjuvant Therapy, Survival Rate, Neoadjuvant chemoradiotherapy, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Body Composition, Female, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Aim: To establish the correlation between changes in body composition after neoadjuvant chemoradiotherapy (nCRT) and postoperative outcomes, in patients with advanced low rectal cancer. Methods: Patients with clinical stage T≥3 or N+ rectal cancer who underwent nCRT and surgical resection were studied. Skeletal muscle, visceral, and subcutaneous fat cross-sectional area were measured by computed tomography before and after nCRT. Postoperative morbidity, pathologic response to nCRT, overall and disease-free survival was assessed. Results: Fifty-two patients, median age 62 (range 32-79) were studied. A skeletal muscle loss >2% significantly correlated with a shorter disease-free survival both in the overall population (P = 0.048) and in the subgroup of N0 patients (P = 0.048). A subcutaneous fat loss >5% was also associated with a shorter disease-free survival (P = 0.012) in the whole population. Conclusions: Skeletal muscle loss, after neoadjuvant chemoradiotherapy, negatively impacts on disease-free survival in surgically treated rectal cancer patients.

Published
2020
Full Text
View/download PDF

7. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer

Author

Claudio Bassi, Mirko D'Onofrio, Luca Gianotti, Kim C. Honselmann, Cristina R. Ferrone, Marta Sandini, Manuel Patino, Dushyant V. Sahani, Carlos Fernandez-del Castillo, Matteo Catania, Alessandra Auriemma, Keith D. Lillemoe, Maria C Salandini, Salvatore Paiella, Anna Damascelli, Marco Braga, Davide Ippolito, Giorgia Tedesco, G. Carrara, Luca Riva, Giulia Cristel, Carlos A Alvarez-Pérez, Raffaella Casolino, Sandini, M, Patino, M, Ferrone, C, Alvarez-Perez, C, Honselmann, K, Paiella, S, Catania, M, Riva, L, Tedesco, G, Casolino, R, Auriemma, A, Salandini, M, Carrara, G, Cristel, G, Damascelli, A, Ippolito, D, D'Onofrio, M, Lillemoe, K, Bassi, C, Braga, M, Gianotti, L, Sahani, D, and Fernandez-Del Castillo, C

Subjects
Male, medicine.medical_specialty, SURGERY, medicine.medical_treatment, Pancreatic cancer, neoadjuvant therapy, Urology, Adipose tissue, Antineoplastic Agents, DUCTAL ADENOCARCINOMA, THERAPY, SARCOPENIA, 03 medical and health sciences, 0302 clinical medicine, Pancreatectomy, Interquartile range, CACHEXIA, Medicine, Humans, Prospective Studies, ESOPHAGOGASTRIC CANCER, Prospective cohort study, Neoadjuvant therapy, Original Investigation, Neoplasm Staging, business.industry, Retrospective cohort study, Chemoradiotherapy, Middle Aged, CHEMOTHERAPY, medicine.disease, Prognosis, Combined Modality Therapy, Neoadjuvant Therapy, Pancreatic Neoplasms, 030220 oncology & carcinogenesis, Sarcopenia, OBESITY, PANCREATICODUODENECTOMY, Body Composition, SKELETAL-MUSCLE, 030211 gastroenterology & hepatology, Female, business
Abstract

IMPORTANCE: Sarcopenia and sarcopenic obesity have been associated with poor outcomes in unresectable pancreatic cancer (PC). Neoadjuvant treatment (NT) is used increasingly to improve resectability; however, its effects on fat and muscle body composition have not been characterized. OBJECTIVES: To evaluate whether NT affects muscle mass and adipose tissue in patients with borderline resectable PC (BRPC) and locally advanced PC (LAPC) and determine whether there were potential differences between patients who ultimately underwent resection and those who did not. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study conducted at 4 academic medical centers, 193 patients with BRPC and LAPC undergoing surgical exploration after NT who had available computed tomographic scans (both at diagnosis and preoperatively) and confirmed pancreatic ductal adenocarcinoma were evaluated. The study was conducted from January 2013 to December 2015. Data analysis was performed from September 2016 to May 2017. Measurement of body compartments was evaluated with volume assessment software before and after NT. A radiologist blinded to the patient outcome assessed the areas of skeletal muscle, total adipose tissue, and visceral adipose tissue through a standardized protocol. EXPOSURES: Receipt of NT. MAIN OUTCOMES AND MEASURES: Achievement of pancreatic resection at surgical exploration after the receipt of NT. RESULTS: Of the 193 patients with complete radiologic imaging available after NT, 96 (49.7%) were women; mean (SD) age at diagnosis was 64 (11) years. Most patients received combined therapy with fluorouracil, irinotecan, oxaliplatin, leucovorin, and folic acid (124 [64.2%]) and 86 (44.6%) received chemoradiotherapy as well. The median interval between pre-NT and post-NT imaging was 6 months (interquartile range [IQR], 4-7 months). All body compartments significantly changed. The adipose compound decreased (median total adipose tissue area from 284.0 cm(2); IQR, 171.0-414.0 to 250.0 cm(2); IQR, 139.0-363.0; P

Published
2018

8. Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care.

Author

DE Bastiani R, Lopetuso LR, DE Bastiani M, Bacchin P, Benedetto E, Boscariolo L, Caneve R, Chesani F, Chiumeo F, Civic Z, Dainese A, DE Polo M, Disclafani G, Grattagliano I, Mana O, Mancuso M, Mastronuzzi T, Pati A, Pirrotta E, Salandini M, Sanna G, Scoglio R, Severino P, Tosetti C, Turnava L, Zamparella M, Elisei W, Gasbarrini A, and Tursi A

Subjects
Humans, Child, Rifaximin therapeutic use, Retrospective Studies, Prevalence, Lactulose therapeutic use, Methane, Primary Health Care, Proton Pump Inhibitors adverse effects, Intestine, Small
Abstract

Background: Although proton pump inhibitor (PPI) drugs have considered able to induce small intestinal bacterial overgrowth (SIBO), no data are so far available from primary care (PC). We assessed the prevalence of SIBO and methane (CH4) production consequent to chronic PPI therapy using Lactulose Breath Test (LBT). Secondary aim was to explore the possible role of rifaximin in treating PPI-induced SIBO patients., Methods: One hundred twenty-five gastroesophageal reflux disease patients, constantly treated with PPI for at least 6 months and undergoing to LBT, were retrospectively assessed. An age-matched control population (control) of 100 patients, which had not used PPI in the last 6 months, was also enrolled. In the PPI group, SIBO positive patients and CH4 producers were treated with rifaximin 1200 mg/daily for 14 days and re-checked with LBT one month after the end of treatment. The area under the curve (AUC) before and after treatment was also calculated for both SIBO positive patients and CH4 producers., Results: In the PPI group, SIBO prevalence was significantly higher vs. controls (38/125 [30.4%] vs. 27/100 [27%], P<0.05). 77/125 (61.6%) PPI patients were found to be CH4 producers vs. 21/100 (21%) controls (P<0.05). Among SIBO patients in the PPI group, 34 (89.4%) were also CH4 producers vs. 17/27 (63%) controls (P<0.05). After treatment, LBT resulted negative in 15/22 SIBO patients (68.1%) (P<0.05) and in 18/34 CH4 producers (52.9%) (P<0.05). At the AUC analysis, an overall reduction of 54.2% for H2 in SIBO patients and of 47.7% for CH4 was assessed after rifaximin treatment (P<0.05)., Conclusions: Our data showed that chronic use of PPI could be able to increase the prevalence of SIBO and to shift the intestinal microbial composition towards a CH4-producing flora. rifaximin could represent a useful therapeutical option for PPI-induced SIBO and for modulating CH4-producing flora.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results